天宇股份布立西坦原料药获得CEP证书

Core Viewpoint - Tianyu Co., Ltd. has received the European Pharmacopoeia Certificate of Suitability (CEP) for the active pharmaceutical ingredient Brivaracetam, which is used as an adjunctive treatment for partial seizures, particularly in patients who do not respond adequately to other antiepileptic drugs [1] Group 1 - Tianyu Co., Ltd. announced the receipt of the CEP certificate from the European Medicines Agency on August 1 [1] - Brivaracetam is specifically indicated for the adjunctive treatment of partial seizures [1] - The certification highlights the company's commitment to meeting European quality standards for its pharmaceutical products [1]